Ibio Inc represents a strong set of values and corporate philosophy. The company focuses on advancing plant-based biopharmaceutical technologies to provide innovative solutions for various diseases. By combining their expertise in molecular biology and genetic engineering, Ibio aims to develop therapies and vaccines that are cost-effective, efficient, and accessible. Their commitment to sustainability and social responsibility is evident in their efforts to address global health challenges. Ibio Inc values collaboration, integrity, and continuous improvement to deliver high-quality biologics. With their dedication to research and development, Ibio Inc strives to make a positive impact in the field of biotechnology.

Ibio Inc is primarily present in the United States of America.

Ibio Inc has achieved several significant milestones over the years. One key achievement is the successful development of their plant-based protein expression technology platform known as FastPharming System. This platform allows for rapid production of biopharmaceuticals. Additionally, the company has made strides in partnership collaborations, including an agreement with AzarGen Biotechnologies to develop and manufacture biosimilar products. Ibio Inc has also made progress in advancing their own pipeline, with the initiation of clinical trials for their lead candidate IBIO-100. These milestones highlight the company's dedication to advancing biopharmaceutical innovation and establishing strong partnerships for future growth.

Ibio Inc is a biotechnology company that specializes in the development and manufacture of therapeutic proteins. Established in 2008, the company is headquartered in Bryan, Texas. Ibio Inc focuses on developing proprietary products and technologies for the treatment of various diseases, including cancer, infectious diseases, and autoimmune disorders. With its advanced plant-based protein expression platform, Ibio Inc enables efficient, cost-effective, and scalable production of biologics. The company has formed successful partnerships with major pharmaceutical companies, leveraging its expertise in protein expression and process development. Notably, Ibio Inc has a strong commitment to addressing unmet medical needs through innovative and sustainable solutions.

The main competitors of Ibio Inc in the market are companies such as Emergent BioSolutions, Inc., Novavax Inc., and Regeneron Pharmaceuticals Inc.

Ibio Inc is primarily active in the biotechnology industry.

The business model of Ibio Inc is focused on the development and commercialization of plant-based biopharmaceutical products. The company utilizes its proprietary technology, the iBioLaunch platform, to produce high-quality, cost-effective biotherapeutics and vaccines. With a focus on speed, scalability, and flexibility, Ibio Inc partners with pharmaceutical and biotechnology companies to advance their product development and manufacturing objectives. By leveraging the advantages of plant-based systems, Ibio Inc aims to provide efficient production solutions for a wide range of medical conditions, including cancer, infectious diseases, and autoimmune disorders.

Το Ibio P/E είναι -0,02.

Το KUV της εταιρείας Ibio είναι 44,73.

Το AlleAktien Qualitätsscore για το Ibio είναι 4/10.

Ο κύκλος εργασιών του αναμενόμενη Ibio είναι 25.500,00 USD.

Το αναμενόμενη Ibio κέρδος είναι -65,15 Εκ. USD.

Ibio Inc is a company specialized in the development and production of innovative vaccines and therapeutics. Its business model is based on three different divisions: the development of vaccines and therapeutics, the production of pharmaceutical ingredients, and the development and production of plant proteins.

Η Ibio καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Ibio αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Ibio είναι US4510332038.

Το WKN της Ibio είναι A2JNBU.

Ο τίκερ της Ibio είναι IBIO.

Κατά τους τελευταίους 12 μήνες η Ibio κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Ibio προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Ibio ανέρχεται σήμερα στο .

Ibio πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Ibio πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Ibio ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Ibio από την 18/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 18/9/2024.

Η τελευταία μερίσματος έγινε στις 18/9/2024.

Το έτος 2023, η Ibio διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Ibio καταβάλλονται σε USD.